Research
Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist, provides greater HbA1c reduction and weight loss compared to semaglutide 1 mg in patients with Type 2 Diabetes.
If you need significant weight loss and blood sugar control, ask your doctor about tirzepatide. It may work better than older GLP-1 drugs like semaglutide 1 mg, but it is more expensive.
GoodSupportsHIGH confidence
Tirzepatide, a GLP-1/GIP receptor agonist, has been shown to be slightly more effective than 1 mg semaglutide at reducing HbA1c in patients with T2D over a 40-week period at doses of 5 mg, 10 mg, and 15 mg (−2.0 to −2.3 percentage point reduction with tirzepatide vs −1.9 percentage point reduction with 1 mg semaglutide)... Tirzepatide has also demonstrated greater weight loss compared to placebo and 1 mg semaglutide in individuals with and without T2D
Why this rating
Supported by randomized trials, but comparison is limited to 1 mg semaglutide, not 2.4 mg.
Source
Pharmacologic Therapies for Type 2 Diabetes
Bryan Kuo et al. · NEJM Evidence · 2025
DOI 10.1056/evidra2400265
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce major adverse cardiovascular events (MACE) and heart failure hospitalizations in patients with type 2 diabetes, independent of glycemic control.Strong
- SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →